Reading Time: 2 minutes

LOS ANGELES–(BUSINESS WIRE)–$CORV–Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Correvio Pharma Corporation (“Correvio” or the “Company”) (NASDAQ: CORV) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On December 6, 2019, U.S. Food and Drug Administration (“FDA”) staffers who reviewed the Company’s resubmitted New Drug Application (“NDA”) for Brinavess found that the drug’s benefits did not offset its risks because Brinavess was associated with “serious liabilities” including irregular heartbeat, low blood pressure, and death.

On this news, Correvio’s share price fell $0.86 per share, or nearly 40%, to close at $1.30 per share on December 6, 2019, thereby injuring investors.

Then, on December 10, 2019, the FDA’s Cardiovascular and Renal Drugs Advisory Committee (“RDAC”) voted 11-2 against the resubmitted NDA, noting that the benefit-risk profile for Brinavess was inadequate to support approval.

On this news, Correvio’s share price further fell $0.94 per share, or more than 67%, to close at $0.46 per share on December 11, 2019, thereby injuring investors further.

If you purchased Correvio securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles H. Linehan, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Glancy Prongay and Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224
[email protected]